How the GLP-1 receptor agonist market could hit $168bn by 2033
In the past few years, there has been a significant increase in the use of GLP-1 receptor agonists as a treatment for Type 2 diabetes and obesity.
Datwyler
Safety first: Mitigating patient safety concerns in parenteral packaging
Drug lifecycle management strategies and the role of parenteral packaging
Designing parenteral packaging for the sensitivities of large molecule injectables
Aiming for perfection and zero defects in coronavirus vaccine development
